OPINION DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

被引：77

作者：

Sinicrope, Frank A. ^{[1
,2
]}

机构：

[1] Mayo Clin, Div Oncol, Rochester, MN 55905 USA

[2] Mayo Canc Ctr, Rochester, MN 55905 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2010年 / 7卷 / 03期

关键词：

HMLH1 PROMOTER HYPERMETHYLATION; NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE-INSTABILITY; IMMUNOHISTOCHEMISTRY; 5-FLUOROURACIL; FLUOROURACIL; PROGNOSIS; LEUCOVORIN; EXPRESSION; IRINOTECAN;

D O I：

10.1038/nrclinonc.2009.235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

引用

页码：174 / 177

页数：4

共 36 条

[1] Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J].

Arnold, CN ;

Goel, A ;

Boland, CR .

INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :66-73

[2] Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer [J].

Barrow, E. ;

McMahon, R. ;

Evans, D. G. ;

Levine, E. ;

Hill, J. .

BRITISH JOURNAL OF SURGERY, 2008, 95 (07) :868-875

[3] Microsatellite instability and colorectal cancer prognosis [J].

Benatti, P ;

Gafà, R ;

Barana, D ;

Marino, M ;

Scarselli, A ;

Pedroni, M ;

Maestri, I ;

Guerzoni, L ;

Roncucci, L ;

Menigatti, M ;

Roncari, B ;

Maffei, S ;

Rossi, G ;

Ponti, G ;

Santini, A ;

Losi, L ;

Di Gregorio, C ;

Oliani, C ;

de Leon, MP ;

Lanza, G .

CLINICAL CANCER RESEARCH, 2005, 11 (23) :8332-8340

[4] Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 [J].

Bertagnolli, Monica M. ;

Niedzwiecki, Donna ;

Compton, Carolyn C. ;

Hahn, Hejin P. ;

Hall, Margaret ;

Damas, Beatrice ;

Jewell, Scott D. ;

Mayer, Robert J. ;

Goldberg, Richard M. ;

Saltz, Leonard B. ;

Warren, Robert S. ;

Redston, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1814-1821

[5]

Boland CR, 1998, CANCER RES, V58, P5248

[6] Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].

Carethers, JM ;

Chauhan, DP ;

Fink, D ;

Nebel, S ;

Bresalier, RS ;

Howell, SB ;

Boland, CR .

GASTROENTEROLOGY, 1999, 117 (01) :123-131

[7]

DEGRAMONT A, 2007, J CLIN ONCOL, V25, pA4007

[8] BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer [J].

Deng, GR ;

Bell, I ;

Crawley, S ;

Gum, J ;

Terdiman, JP ;

Allen, BA ;

Truta, B ;

Sleisenger, MH ;

Kim, YS .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :191-195

[9] BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing [J].

Domingo, E ;

Laiho, P ;

Ollikainen, M ;

Pinto, M ;

Wang, L ;

French, AJ ;

Westra, J ;

Frebourg, T ;

Espín, E ;

Armengol, M ;

Hamelin, R ;

Yamamoto, H ;

Hofstra, RMW ;

Seruca, R ;

Lindblom, A ;

Peltomäki, P ;

Thibodeau, SN ;

Aaltonen, LA ;

Schwartz, S .

JOURNAL OF MEDICAL GENETICS, 2004, 41 (09) :664-668

[10] Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer [J].

Elsaleh, H ;

Joseph, D ;

Grieu, F ;

Zeps, N ;

Spry, N ;

Iacopetta, B .

LANCET, 2000, 355 (9217) :1745-1750

← 1 2 3 4 →